Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179641 | 0.85 | GAA (0.46) | LMNAGAAALDH1A1SMN1; SMN2F2 | |
| SCHEMBL3618544 | 0.84 | KMT2A (0.47) | LMNAGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1178745 | 0.82 | ALDH1A1 (0.52) | GAAALDH1A1HTTF2PRSS1 | |
| SCHEMBL1178964 | 0.74 | CA2 (0.47) | LMNAALDH1A1F2PRSS1PRSS2 | |
| SCHEMBL12444191 | 0.74 | GAA (0.63) | LMNAGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL10682761 | 0.72 | LMNA (0.53) | LMNAGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL29751653 | 0.72 | LMNA (0.67) | LMNAGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5414075 | 0.71 | SMN1; SMN2 (0.53) | LMNAGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL10195900 | 0.71 | GAA (0.59) | LMNAGAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL307938 | 0.71 | ALDH1A1 (0.78) | LMNAGAAALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9065146-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-06-23 | — | — | US | disclosed |
| US-8551662-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8029935-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20110229771-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| US-7981553-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-07-19 | — | — | US | disclosed |
| US-20110159380-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2305671-A1 | Thiophene and thiazole derivatives as CHK1 inhibitors | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100227226-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100021823-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-01-28 | — | — | US | disclosed |
| US-7575833-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20070238025-A1 | NONAQUEOUS ELECTROLYTE AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-10-11 | — | — | US | disclosed |
| US-7223502-B2 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1732920-A2 | THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005066163-A2 | THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-20050118512-A1 | Nonaqueous electrolyte and lithium secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | CHEK1, CHKA, CHEK2 | LMNA 4241/4885GAA 2518/4885ALDH1A1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.